APRV has allways been a tough "sell" to our pulmonologists in Casper. Often by the time it is considered, usually by the most talented RT's, it is deemed futile or at best experimental. It has been my experience in the past that APRV when employed early and often is helpful in avoiding ARDS or at least decreasing the duration of the disease. Also, while transthorasic flow return issues can be present with high pressures, this can be dealt with, with inotrops if tolerated. Count of the RT to guide this therapy, they are skilled at recognizing sutle and hidin changes in lung compliance.